Stephen Hoge - Feb 27, 2024 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
President
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Feb 27, 2024
Transactions value $
$0
Form type
4
Date filed
2/29/2024, 04:32 PM
Previous filing
Feb 23, 2024
Next filing
Mar 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MRNA Common Stock 1.51M Feb 27, 2024 Direct
holding MRNA Common Stock 4.12K Feb 27, 2024 By Valhalla, LLC
holding MRNA Common Stock 152K Feb 27, 2024 By Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Award $0 +43.9K $0.00 43.9K Feb 27, 2024 Common Stock 43.9K $96.20 Direct F2
transaction MRNA Restricted Stock Units Award $0 +23K $0.00 23K Feb 27, 2024 Common Stock 23K $0.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F2 25% of this option will vest and become exercisable on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F3 25% of the shares subject to this restricted stock unit award will vest on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.